Ultragenyx Presentations & Investor Relations material

Ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. Our company is led by an experienced management team in rare disease therapeutics. Recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. We are also working with regulatory agencies to design and conduct quality studies that meet the requirements for life approval. We are creating an improved drug model for successful rare disease development that increases efficiency and effectiveness by changing the way the treatment process is conducted and we believe that if you are looking for a great opportunity to join our team of highly motivated individuals and transform the high-value pipeline of rare disease therapeutics into